Previous 10 | Next 10 |
-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (former...
FOSTER CITY, Calif. and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potential...
- INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single agent and in combination with pimivalimab (pimi) - - Patient with advanced biliary tract cancer who failed multiple lines of prior treatment including a PD-1 inhibitor showed a durable partial res...
Raymond James has downgraded Jounce Therapeutics ( NASDAQ: JNCE ) to outperform from strong buy as full phase 2 data on immunotherapy JTX-2064 now won't be available until H1 2023, instead of the end of this year. The firm also lowered its price target to $3 from $16 (~156...
Jounce Therapeutics, Inc. (JNCE) Q3 2022 Results Earnings Conference Call November 10, 2022, 08:00 AM ET Company Participants Eric Laub - Vice President-Investor Relations Richard Murray - Chief Executive Officer and President Hugh Cole - Chief Operating Officer ...
Jounce Therapeutics press release ( NASDAQ: JNCE ): Q3 GAAP EPS of -$0.60 beats by $0.04 . As of September 30, 2022, cash, cash equivalents and investments decreased to $130.3M, compared to $220.2M as of December 31, 2021. The decrease was due to operating expenses inc...
- INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical posters on JTX-1484 and LILRB family at SITC 202...
Jounce Therapeutics ( NASDAQ: JNCE ) is scheduled to announce Q3 earnings results on Thursday, November 10th, before market open. The consensus EPS Estimate is -$0.64 Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. For furthe...
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today earning a $15.0 million clinical milestone payment from ...
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...